<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04702633</url>
  </required_header>
  <id_info>
    <org_study_id>APHP201309</org_study_id>
    <nct_id>NCT04702633</nct_id>
  </id_info>
  <brief_title>Immuno-molecular Approaches for Non-invasive Diagnosis of Prostate Cancer</brief_title>
  <acronym>PROSTA-PAP</acronym>
  <official_title>Non-invasive Isolation and Characterization of Prostate Tumor Cells for Prostate Cancer Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rarecells Diagnostics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to isolate and characterize tumor cells non-invasively from&#xD;
      biological samples in patients with prostate cancer and demonstrate the ability to identify&#xD;
      the presence and number of tumor cells before prostate biopsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate cancer is one of the most frequently diagnosed cancers and a leading cause of cancer&#xD;
      death in men worldwide. Existing methods of diagnosis and monitoring of prostate cancer are&#xD;
      inadequate due to their invasiveness, inaccuracy, cost, access uneven, etc., making difficult&#xD;
      the diagnosis and patient's follow up. New techniques and methods are necessary to improve&#xD;
      diagnosis.&#xD;
&#xD;
      Biological liquids might represent an attractive target to isolate prostate tumour cells for&#xD;
      these purposes. In recent years, several studies have been carried out with the aim of&#xD;
      reducing and / or avoiding the limits of sensitivity and specificity of current methods of&#xD;
      screening for prostate cancer and thus obtain new biomarkers for the diagnosis and / or&#xD;
      non-invasive monitoring.&#xD;
&#xD;
      However, due to technical and technological difficulties few studies have been performed to&#xD;
      investigate the non-invasive isolation and direct analysis of tumour cells. Our project is&#xD;
      therefore an innovative project which aims to study a new approach for the early diagnosis of&#xD;
      prostate cancer, with better sensitivity and specificity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2021</start_date>
  <completion_date type="Anticipated">March 19, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 19, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence and number of prostate tumour cells in biological samples</measure>
    <time_frame>One month after biopsy or until the histological diagnosis will be obtained</time_frame>
    <description>Cell enrichment will be carried out using the ISET® (Isolation by SizE of Tumor/Trophoblastic cells) technology. Identification will be performed by different spectroscopic and/or immune-molecular and/or cytological approaches</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Confirmed diagnosis group</arm_group_label>
    <description>Patients with a diagnosis of prostate cancer (metastatic or advanced) before prostatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-diagnosis group</arm_group_label>
    <description>Patients undergoing prostate biopsy in the context of prostate cancer diagnosis: PSA increases, and / or abnormal digital rectal examination (DRE) and / or an MRI detected signal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Results obtained by biopsy and MRI results.</intervention_name>
    <description>Results obtained by biopsy and MRI results.</description>
    <arm_group_label>Confirmed diagnosis group</arm_group_label>
    <arm_group_label>Pre-diagnosis group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical data</intervention_name>
    <description>Clinical data</description>
    <arm_group_label>Confirmed diagnosis group</arm_group_label>
    <arm_group_label>Pre-diagnosis group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biological samples (blood, plasma, urines) and paraffin-embedded tissue cuts.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients consulting the urology department of Cochin Hospital with an indication for&#xD;
        prostate biopsy or as part of the monitoring of prostate cancer may be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of localized or metastatic prostate cancer.&#xD;
&#xD;
          -  No prior or other oncological treatment.&#xD;
&#xD;
          -  Patients undergoing prostate biopsy in the context of prostate cancer diagnosis.&#xD;
&#xD;
          -  Patients with an elevation of PSA (Prostate Specific Antigen), an abnormality on the&#xD;
             rectal examination and / or an MRI signal motivating a prostate biopsy,&#xD;
&#xD;
          -  Patients informed and not opposed to participating in the research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients not affiliated with French social security.&#xD;
&#xD;
          -  Patients unable to understand the protocol.&#xD;
&#xD;
          -  Patients diagnosed with another type of cancer within the past 5 years.&#xD;
&#xD;
          -  Patients prostatectomized and/or treated for prostate cancer.&#xD;
&#xD;
          -  Patients who wear a bladder catheter&#xD;
&#xD;
          -  Patients under guardianship or curatorship&#xD;
&#xD;
          -  Patients under AME&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrizia PATERLINI-BRECHOT, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>INSERM and Rarecells Diagnostics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien ANRACT, MD</last_name>
    <phone>+ 33(0)1 58 41 33 55</phone>
    <email>julien.anract@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie BENHAMMANI-GODARD</last_name>
    <phone>0033158411190</phone>
    <email>marie.godard@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien ANRACT, MD</last_name>
      <phone>+ 33(0)1 58 41 33 55</phone>
      <email>julien.anract@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Laura Nalleli GARRIDO CASTILLO, MSc</last_name>
      <phone>00 33 1 40 61 56 06</phone>
      <email>laura.garrido@rarecells.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Liquid biopsy</keyword>
  <keyword>Biological samples</keyword>
  <keyword>Non-invasive diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

